---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-015975"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T15:08:37.349567+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Virios receives Nasdaq bid price deficiency notice; has 180 days to regain compliance

## Summary
- Nasdaq notice on Nov 1, 2022: bid price below $1.00 for 30 consecutive business days.
- Compliance deadline is May 1, 2023; can cure by closing at $1.00+ for 10 consecutive days.
- If not compliant, may qualify for second 180-day period or face delisting and possible appeal.
- Company will monitor bid price and may consider options to regain compliance.
- Common stock continues to trade under VIRI on Nasdaq Capital Market for now.

## SEC filing metadata
- accession: 0001558370-22-015975
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837022015975/0001558370-22-015975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837022015975/tmb-20221101x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-015975
- JSON: https://secwatch.observer/filing/0001558370-22-015975.json
- Plain text: https://secwatch.observer/filing/0001558370-22-015975.txt

## Key facts
- Listing & Compliance Notices
  Dogwood Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: November 1, 2022, Virios Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Cap
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837022015975/0001558370-22-015975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.